Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
Zenas BioPharma will host a virtual investor event on obexelimab in IgG4-Related Disease on Tuesday, September 29, 2026, from 8:00 to 9:30 a.m. ET. Management will be joined by Dr. Guy Katz of Massachusetts General Hospital and plans to cover the IgG4-RD treatment landscape, prelaunch preparedness strategies, and the potential commercial opportunity for obexelimab if approved by the FDA.
Key figures
- Drug Name
- obexelimab
- Event date
- 2026-09-29
- Event format
- virtual, 8:00-9:30 a.m. ET
- Bla acceptance
- August 2026
- Pdufa target action date
- May 27, 2027
- Ema maa submission timing
- second half of 2026
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.